



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 01/23/2023 06:45
Last Report Issued 01/23/2023 06:45

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1876U-POS
Patient ID 1876U-POS
Chain 22000382
DOB Not Given
Sex Not Given
Workorder 22000382
Received 01/25/2022

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Results were removed from report on 10/27/2022.

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains drug screen results for Salicylates, Barbiturates, Cannabinoids, and 6-Monoacetylmorphine.

Results for sample 22000382-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
 Phone: (215) 657-4900 Fax: (215) 657-2972
 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
<p>Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).</p>				
Acetyl Fentanyl	See Comment	ng/mL	5.0	
<p>Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).</p> <p>Acetyl Fentanyl is a novel non-prescription synthetic opioid that has been implicated in several deaths.</p>				
Alprazolam	See Comment	ng/mL	100	
<p>Synonym(s): Xanax®</p> <p>Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).</p>				
Cocaine	See Comment	ng/mL	200	
<p>Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).</p>				
Fentanyl	See Comment	ng/mL	10	
<p>Synonym(s): Sublimaze®; Duragesic®</p> <p>Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).</p> <p>Approximately 6% of dose is excreted in the urine as unchanged drug in 3 to 4 days.</p>				
Morphine	See Comment	ng/mL	100	
<p>Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).</p>				
Scope Statement	See Comment			
<p>Comment: The following is a general list of analyte classes included in this screen. The detection of any specific analyte is concentration-dependent. Note, not all known analytes in each specified analyte class are included. Some specific analytes outside of these classes are also included. For a detailed list of all analytes and reporting limits included in this screen, please contact NMS Labs. Amphetamines, Anticonvulsants, Antidepressants, Antihistamines, Antipsychotic Agents, Benzodiazepines, CNS Stimulants, Cocaine and Metabolites, Hallucinogens, Hypnotics, Hypoglycemics, Muscle Relaxants, Non-Steroidal Anti-Inflammatory Agents, Opiates and Opioids.</p>				

Results for sample 22000382-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

50011U Barbiturates Confirmation, Urine

Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)

Butalbital The disposition of butalbital has not been well studied in humans.	5.0	mcg/mL	0.20	
Pentobarbital Less than 1% of a dose is eliminated in the urine as unchanged drug.	5.0	mcg/mL	0.20	
Secobarbital Synonym(s): Seconal® Secobarbital undergoes extensive biotransformation. However, approximately 5% of secobarbital is excreted unchanged in the urine within 2 days.	5.0	mcg/mL	0.20	
Phenobarbital Synonym(s): Luminal® For patients on chronic therapy, a mean of 20% (range, 12 - 55%) of the dose is excreted unchanged in the 24 hour urine.	5.0	mcg/mL	0.50	

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

50012U Benzodiazepines Confirmation, Urine

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Diazepam Synonym(s): Valium®	50	ng/mL	20	
Nordiazepam Synonym(s): Chlordiazepoxide Metabolite	50	ng/mL	20	
Oxazepam	50	ng/mL	20	

Results for sample 22000382-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Lists various benzodiazepines and their metabolites with results of 50 ng/mL and reporting limits ranging from 5.0 to 20.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

50013U Cannabinoids Confirmation, Urine

Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)

Results for sample 22000382-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Delta-9 Carboxy THC - Total Synonym(s): Inactive Metabolite	50	ng/mL	5.0	

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

50014U Cocaine and Metabolites Confirmation, Urine

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Benzoylcegonine Synonym(s): Cocaine Degradation Product	100	ng/mL	50	
Cocaine	20	ng/mL	10	
Cocaethylene Synonym(s): Cocaine/Ethanol By-Product	20	ng/mL	10	

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

50015U Methadone and Metabolite Confirmation, Urine

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Methadone Synonym(s): Dolophine®	500	ng/mL	200	
EDDP Synonym(s): Methadone Metabolite	500	ng/mL	200	

In maintenance subjects: Up to 50000 ng of
Methadone plus Methadone Metabolites/mL Urine.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

50016U Opiates - Free (Unconjugated) Confirmation, Urine

Results for sample 22000382-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Dihydrocodeine / Hydrocodol - Free, Codeine - Free, Morphine - Free, Hydrocodone - Free, 6-Monoacetylmorphine - Free, Hydromorphone - Free, Oxycodone - Free, Oxymorphone - Free.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52058U Ketamine and Metabolite Confirmation, Urine

Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Row: Norketamine, 250, ng/mL, 100.

Results for sample 22000382-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Over a 72 hour period, approximately 1.6% of a single dose of ketamine is eliminated in urine as unchanged drug; the remainder is found as unconjugated norketamine. The mean urine concentration of norketamine in abusers of ketamine was reported to be 1200 ng/mL.				
Ketamine	250	ng/mL	100	
Synonym(s): Ketalar® Over a 72 hour period, approximately 2.3% of a single dose of ketamine is eliminated in urine as unchanged drug; the remainder is found as unconjugated and conjugated ketamine metabolites. In healthy young adults given a single 5 mg oral dose, the mean peak urine concentration of ketamine 2 hours post-dose was approximately 800 ng/mL. The mean urine concentration of ketamine in abusers of the drug was reported to be 1100 ng/mL.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52456U Promethazine Confirmation, Urine

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Promethazine	50	ng/mL	5.0	
Synonym(s): Phenergan®				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52481U D/L Methorphan, Dextrorphan & Levorphanol Confirmation - Total, Urine

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Dextrorphan / Levorphanol - Total	500	ng/mL	100	
Synonym(s): Levo-Dromoran®				

Results for sample 22000382-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

Dextrorphan is a metabolite of dextromethorphan, an over the counter antitussive. Levorphanol is an analgesic indicated for the relief of moderate to severe pain. Its potency is approximately four to five times that of morphine.

Note: This analysis cannot distinguish between dextrorphan and its stereoisomer levorphanol.

Dextro / Levo Methorphan - Total	50	ng/mL	10	
----------------------------------	----	-------	----	--

This test is not chiral specific; therefore, Dextromethorphan and/or Levomethorphan may be present.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52482U Citalopram Confirmation, Urine

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Citalopram / Escitalopram	50	ng/mL	5.0	
---------------------------	----	-------	-----	--

Synonym(s): Celexa® / Lexapro®

For Citalopram, approximately 32% of an oral dose is eliminated in urine as unchanged drug following chronic daily administration.

For Escitalopram, approximately 8% of a dose is eliminated in urine as unchanged drug.

This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Patients who have taken Racemic Citalopram (Celexa®), as opposed to Escitalopram (Lexapro®), within the past 3 days may have falsely elevated values.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52483U Amphetamines Confirmation, Urine

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Ephedrine	500	ng/mL	50	
-----------	-----	-------	----	--

Results for sample 22000382-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Pseudoephedrine, Phenylpropanolamine, Norpseudoephedrine, Amphetamine, Phentermine, Methamphetamine, MDA, and MDMA.

Results for sample 22000382-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22000382-001
Matrix Urine
Patient Name 1876U-POS
Patient ID 1876U-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

3,4-Methylenedioxyamphetamine (MDMA) is a sympathomimetic compound with mixed stimulant and hallucinogenic properties. Users report that MDMA promotes empathy and feelings of love, or emotional closeness to others. Users also report visual and tactile hallucinations, confusion, agitation and coma. Acutely, users typically have elevated pulse and blood pressure and dilated pupils, with slow reaction to light. Drivers arrested under suspicion of MDMA intoxication generally displayed erratic driving, weaving, failure to obey stop signs, speeding and involvement in collisions. The mixed stimulant and hallucinogenic effects of recreational use of this drug create a risk for impairment of the skills needed for safe driving.

MDEA	500	ng/mL	50	
------	-----	-------	----	--

Synonym(s): 3,4-methylenedioxyethylamphetamine; Eve

3,4-methylenedioxyethylamphetamine (MDEA) is a sympathomimetic compound with mixed stimulant, and hallucinogenic properties. Users report that MDEA promotes empathy, and feelings of love, or emotional closeness to others. Users also report visual and tactile hallucinations, confusion, agitation, and coma. Acutely, users typically have elevated pulse and blood pressure, and dilated pupils, with slow reaction to light. The mixed stimulant and hallucinogenic effects of recreational use of this drug create a risk for impairment of the skills needed for safe driving.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.